Preferred Label : pertuzumab;

MeSH note : a HER-2-targeted monoclonal antibody; prevents ERBB2 receptor protein from binding (dimerizing) to other receptors in the HER family;

CISMeF synonym : genetech brand of pertuzumab; omnitarg;

MeSH hyponym : Omnitarg, 2C4; rhumab-2C4;

MeSH Related Number : 380610-27-5 (pertuzumab);

Registry Number MeSH : 380610-27-5;

Is substance : O;

UNII : K16AIQ8CTM;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/phesgo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
pertuzumab
pertuzumab
drug combinations
Trastuzumab
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
pertuzumab and trastuzumab
product surveillance, postmarketing
breast neoplasms
neoplasm metastasis
antineoplastic combined chemotherapy protocols
adult
Early-Stage HER2 Positive Breast Cancer
HER2-positive metastatic or locally recurrent unresectable breast cancer,who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
receptor, erbB-2
HER-2 positive breast cancer
aged
drug interactions
pregnancy
breast feeding
ERBB2 protein, human
drug evaluation, preclinical
survival analysis
Docetaxel/Pertuzumab/Trastuzumab Regimen
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
receptor, erbB-2

---
https://www.has-sante.fr/jcms/p_3259931/fr/phesgo
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
pertuzumab and trastuzumab
pertuzumab
Trastuzumab
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
HER2-positive metastatic or locally recurrent unresectable breast cancer,who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
breast neoplasms
neoplasm metastasis
HER2 positive breast cancer
receptor, erbB-2
injections, subcutaneous
Docetaxel/Pertuzumab/Trastuzumab Regimen
evaluation of the transparency committee
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3067188/fr/perjeta
https://www.has-sante.fr/jcms/pprd_2984015/fr/perjeta
2019
false
true
false
false
France
French
antineoplastic combined chemotherapy protocols
Trastuzumab
pertuzumab
adult
breast neoplasms
neoplasm recurrence, local
risk
receptor, erbB-2
treatment outcome
pertuzumab
evaluation of the transparency committee
antibodies, monoclonal, humanized

---
http://conseil-scientifique.public.lu/fr/publications/oncologie/pertuzumab-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
guidelines for drug use
infusions, intravenous
pertuzumab
pertuzumab
HER2 positive breast cancer
breast neoplasms
neoplasm metastasis
neoplasm recurrence, local
Advanced Malignant Neoplasm
Stage IV Breast Cancer AJCC v6 and v7
antineoplastic combined chemotherapy protocols
antineoplastic agents
antibodies, monoclonal, humanized

---
Summary Safety Review - PERJETA (pertuzumab) - Assessing the Potential Risk of Stevens-Johnson Syndrome
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/perjeta-fra.php
2016
false
false
false
Canada
French
English
pertuzumab
pertuzumab
pertuzumab
risk assessment
breast neoplasms
pharmacovigilance
drug information
stevens-johnson syndrome
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
http://www.has-sante.fr/portail/jcms/c_2658570/en/perjeta
http://www.has-sante.fr/portail/jcms/c_2658570/fr/perjeta-pertuzumab-anticorps-monoclonal
2016
false
false
France
French
antineoplastic combined chemotherapy protocols
neoadjuvant therapy
Locally Advanced Malignant Neoplasm
guidelines for drug use
evaluation of the transparency committee
pertuzumab
pertuzumab
pertuzumab
infusions, intravenous
receptor, erbB-2
breast neoplasms
adult
treatment outcome
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60912227
2014
false
false
false
France
French
summary of product characteristics
package leaflet
solution, nos
perfusion
pertuzumab
pertuzumab
perfusion, nos
pertuzumab
solutions
perfusion
solutions
antibodies, monoclonal, humanized

---
https://pgtmsite.files.wordpress.com/2024/01/pertuzumab_position-preliminaire_final.pdf
2014
Canada
drug information
PAX8 Gene Rearrangement
KIT Positive
pertuzumab
NRAS Gene Mutation
SDHB Positive
c-MET Gene Amplification
KRAS Gene Mutation
IDH Gene Family Mutation
Hepatitis C Virus RNA Positive
PAS Positive
FGFR2 Gene Rearrangement
Positive Number
Estrogen Receptor Positive
ANO1 Positive
breast cancer
GNAQ Gene Mutation
FGFR1 Gene Rearrangement
pertuzumab
Human Immunodeficiency Virus Positive
1p/19q Codeletion
HER-2 positive breast cancer
ESR2 Positive
Hepatitis B Virus Surface Antigen Positive
HRAS Gene Mutation
Breast Cancer Therapeutic Procedure
Herero Language
Positive Lymph Node
Positive EBV Test
RET/PTC Rearrangement
FGFR3 Gene Mutation
SDHA Positive
TERT Promoter Mutation
Pertuzumab
MGMT Gene Promoter Methylation
ERG Gene Rearrangement
GNA11 Gene Mutation
Metastatic Malignant Neoplasm in the Breast
breast neoplasms
pertuzumab
ATRX Gene Mutation
ERBB2 Gene Mutation
neoplasm, malignant
Hepatitis B DNA Positive
Hepatitis B Surface Antibody Positive
FGFR3 Gene Rearrangement
BAP1 Gene Mutation
FGFR2 Gene Mutation
PD-L1 Positive
ERBB2 Gene Amplification
CDH1 Gene Mutation
CTNNB1 Gene Mutation
ETV Gene Rearrangement
Progesterone Receptor Positive

---
https://www.ema.europa.eu/medicines/human/EPAR/Perjeta
2013
false
United Kingdom
English
French
Trastuzumab
Docetaxel/Pertuzumab/Trastuzumab Regimen
Pertuzumab/Trastuzumab Regimen
Tyrosine Kinase Inhibitors
pertuzumab
pertuzumab
antineoplastic combined chemotherapy protocols
adult
breast neoplasms
neoplasm metastasis
neoplasm recurrence, local
receptor, erbB-2
breast neoplasms
Biomarkers, Tumor
infusions, intravenous
aged
pregnancy
breast feeding
fertility
treatment outcome
clinical trials, phase iii as topic
receptor, erbB-2
summary of product characteristics
package leaflet
syndication feed
disease-free survival
Progression-Free survival
survival analysis
drug evaluation, preclinical
HER2 positive breast cancer
drug approval
europe
taxoids
antibodies, monoclonal, humanized
Docetaxel
genes, erbB-2
pertuzumab

---
http://www.has-sante.fr/portail/jcms/c_1638593/fr/perjeta
http://www.has-sante.fr/portail/upload/docs/evamed/CT-12851_PERJETA%20INS_Avis2_CT12851.pdf
2013
false
France
French
guidelines for drug use
evaluation of the transparency committee
pertuzumab
pertuzumab
pertuzumab
infusions, intravenous
receptor, erbB-2
neoplasm metastasis
breast neoplasms
adult
neoplasm recurrence, local
antineoplastic combined chemotherapy protocols
treatment outcome
clinical trials, phase iii as topic
disease-free survival
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
Summary Basis of Decision (SBD) for Perjeta
Pertuzumab, 420 mg/14 mL vial Concentrate, solution for infusion, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00260
2013
false
Canada
English
French
Trastuzumab
drug approval
canada
pertuzumab
pertuzumab
pertuzumab
breast neoplasms
receptor, erbB-2
infusions, intravenous
protein multimerization
neoplasm metastasis
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
treatment outcome
clinical trials, phase ii as topic
clinical trials, phase iii as topic
disease-free survival
summary of product characteristics
survival analysis
taxoids
Docetaxel

---
Nous contacter.
24/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.